Overall, 57% of participants had evidence on PET/MRI of inflammation affecting the heart or lungs.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
Boosters lower the risk of death among adults more than 90% and increase protection against severe disease in children aged 5 to 11 years by 77%, new data reveal.
A 5-year study of US hospital data illustrates trends in E coli and Klebsiella pneumoniae isolates carrying beta-lactamase antibiotic resistance genes.
Among children, COVID-19 was the eighth-leading cause of death from any cause and first in deaths caused by infectious or respiratory disease.
Deaths and struggling health systems are among ongoing concerns, and the group will likely meet again in 3 months to reassess developments.
A randomized trial in Canada finds that COVID-19 patients in the audit and feedback group had lower antibiotic use but similar outcomes to patients treated with standard of care.
The bivalent booster offered additional benefits against symptomatic infection and severe illness, 3 new studies show.
In another COVID development, the FDA pulled its EUA for Evusheld, the last available monoclonal antibody treatment, due to weak activity against the newer circulating subvariants.
Residents not up to date on recommended COVID-19 vaccines were at a 30% to 50% higher risk for infection.
Data show the share of Americans reporting long COVID has dropped over the past 6 months, while another study suggests vaccination may contribute to lower levels of long COVID.
FDA advisers recommend offering just the newer bivalent versions of the vaccine for both primary and booster series.
